Aurobindo Pharma Limited — Updates, 14-08-2026: General Updates
14-08-2026 | 09:38 am
14-08-2026 | 09:38 am
Aurobindo Pharma's subsidiary Eugia Pharma's Unit I received a US FDA Warning Letter. No immediate impact on existing US supplies. This unit contributes only ~2% to overall group revenue, limiting significant financial implications. The company is enhancing compliance.
No comments yet. Be the first to comment!
